AMBIGUOUS RESULTS

Eledon's tegoprubart: all evaluable islet-transplant patients reach insulin independence

An investigator-initiated Chicago trial reports every evaluable patient off insulin more than four weeks post-transplant, with no graft rejection, though the readout comes from a press release, not a peer-reviewed dataset.

By AppliedXLJuly 8, 2026Trial NCT06305286

Executive Summary

Every evaluable patient in a small, ongoing islet-transplant trial testing tegoprubart alongside donor islets reached insulin independence, extending a positive signal first shown in an earlier readout from the same study.
The figure comes from a company press release rather than a posted dataset, and it describes only the subset of patients far enough past transplant to be evaluable, not the full enrolling cohort.
Tegoprubart sits in a CD40-CD40L pathway field with a mixed track record in type 1 diabetes, and this trial is one of a handful still generating human data against that history.
The study has grown its enrollment target sharply as it recruits toward a 2029 primary completion, so this readout is an early marker inside a still-expanding trial rather than its final word.

The disclosure

Eledon Pharmaceuticals said all evaluable patients more than four weeks past islet transplant in the University of Chicago-run trial NCT06305286 reached insulin independence on a tegoprubart-containing, tacrolimus-free regimen, with no graft rejection or tacrolimus-associated toxicities observed. The trial tests immunomodulation with the anti-CD40 ligand antibody in combination with transplanted islet cells in adults with brittle type 1 diabetes, and its registered primary endpoint is the number of participants who are insulin-independent after their first and final transplant. The disclosure did not specify how many of the trial's enrolled patients were evaluable at the time of the update, and it was not accompanied by a posted ClinicalTrials.gov results record. The+1

Probability of Success

Endpoint Met71%

Completes65%

Clinical Significance10%

Regulatory36%

Building on an earlier readout

This is not the trial's first public update. In October 2024, investigators presented interim data at the IPITA/HSCI/Breakthrough T1D Summit showing two of three subjects had achieved insulin independence on the same tacrolimus-free, tegoprubart-containing regimen, with no unexpected adverse events. The newer disclosure describes a larger evaluable group reaching the same result, extending rather than reversing the direction of that earlier signal. NCT06305286

A trial still filling its target

The trial's anticipated enrollment has grown from 3 to 9 to 70 participants since 2024, with the most recent increase recorded in December 2025. That growth in a Phase 1/2 trial reflects the study scaling up recruitment, not a sign of distress. The trial remains in Recruiting status with a primary completion date of March 1, 2029, so the population this readout describes represents an early slice of a cohort still being enrolled. NCT06305286

Where it sits in the field

CD40-CD40L pathway blockade has a limited track record in type 1 diabetes: among CD40-targeted programs tested against the indication, one trial completed and two were terminated, and Eledon's own earlier islet-transplant program using the same antibody under its prior name, AT-1501, was withdrawn twice before this trial launched. Tegoprubart itself is also in testing for kidney transplant rejection, where the same CD40L-blocking mechanism is being evaluated outside the diabetes setting, giving the sponsor a second read on the antibody's tolerability profile across transplant indications. NCT06305286

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.